A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
This 4 arm study will assess the optimal starting dose of Mircera in the treatment of anemia
in patients with non-small cell lung cancer receiving first line myelosuppressive
chemotherapy. Patients will be randomized to receive either Mircera 6.3 micrograms/kg, 9
micrograms/kg or 12 micrograms/kg s.c. every 3 weeks or darbepoetin alfa according to the
approved local label (either 6.75 micrograms/kg s.c. every 3 weeks, or 2.25 micrograms/kg
every week). The anticipated time on study treatment is <3 months and the target sample size
is 100-500 individuals.